Ashwagandha Stress Meta-Analysis: What Does the Research Show?

It is easy to understand the appeal of ashwagandha. After a demanding week, the idea that a botanical ingredient might make everyday pressures feel more manageable sounds reassuring. But the strongest question is not whether one study reported a positive result. It is whether several carefully conducted human studies point in the same direction, how large their effects were, and whether those results apply to the supplement sitting on a store shelf. That is what an ashwagandha stress meta-analysis can help us examine.

Ashwagandha stress meta-analyses suggest that certain studied extracts may improve perceived stress over several weeks, but findings are not completely consistent. A 2024 review reported lower stress scores and cortisol, whereas a 2025 review found lower cortisol without a statistically significant improvement in perceived stress. Newer pooled research is encouraging, yet differences in extracts, trial design, and follow-up prevent a universal conclusion about effectiveness or safety.

Picture two people reading the same label: one wants to understand the science before buying anything, while the other already takes ashwagandha and wonders whether its advertised benefits are realistic. Both deserve more than a positive headline. The most useful answers come from examining actual trial numbers, separating hormones from personal experiences, and recognizing where research on an individual extract ends and claims about a finished product would begin.

What Do Ashwagandha Stress Meta-Analyses Show?

Ashwagandha meta-analyses generally report favorable average results for certain stress-related measures, but they do not all reach the same conclusion. Reviews from 2022 through 2026 pooled randomized controlled trials involving hundreds of adults. Some found improvements in perceived stress, anxiety-related scores, and cortisol; another found lower cortisol without a significant change in perceived stress. These differences limit how broadly the findings can be applied.

A meta-analysis is useful because one small clinical trial can give an incomplete impression of an ingredient. Pooling studies may improve statistical precision and reveal whether positive results are repeated. However, a pooled average cannot erase problems with the original trials. If studies use different extracts, recruit different participants, or ask different questions, a single summary number may conceal important differences. Readers gain more by examining what was tested than by counting how many reviews describe an effect as significant.

Which Clinical Trials Were Included?

The main research base consists of randomized controlled trials, usually comparing an ashwagandha preparation with placebo. In a properly designed trial, random assignment helps limit differences between groups, while blinding reduces the chance that expectations shape reported outcomes. These safeguards are especially important when participants rate feelings such as tension, control, and overload. Still, a trial's reliability also depends on complete reporting, consistent outcome measurement, and whether enough participants finished the intervention.

The 2022 systematic review included 12 trials and 1,002 participants; the 2024 review included nine trials and 558 participants. The 2025 review identified seven studies measuring cortisol and six measuring perceived stress, covering 488 participants in its included evidence. A 2026 dose-response review included 22 trials and 1,391 adults. These figures cannot be added together, because several primary trials appear in more than one review. Participants, extracts, study lengths, and measurement tools also differed, so the totals alone do not tell us how reliable a conclusion is.

Published review	Evidence included	Main reported result	Reading the result carefully
2022 systematic review	12 trials; 1,002 adults	Lower pooled stress and anxiety scores	Evidence certainty rated low; high heterogeneity
2024 stress and anxiety review	9 trials; 558 participants	Lower perceived stress, anxiety scores, and serum cortisol	Extracts and study protocols differed
2025 cortisol and stress review	7 cortisol studies; 6 perceived-stress studies; 488 participants	Lower cortisol; no significant pooled perceived-stress improvement	Biological and subjective results diverged
2026 dose-response review	22 trials; 1,391 adults	Favorable pooled stress-related results	Authors still called for better-quality research

What Did the 2022, 2024, and 2026 Reviews Find?

The 2022 review reported a standardized mean difference of −1.75 for stress compared with placebo, alongside marked variation among studies. Its authors rated evidence certainty as low. The 2024 review found an average difference of −4.72 points on the Perceived Stress Scale, with a 95% confidence interval from −8.45 to −0.99. It also reported differences in anxiety scores and serum cortisol. These numbers suggest potentially helpful average effects in the studied groups, not a predictable response in every individual.

The 2026 analysis broadened the research base to 22 randomized trials. It reported favorable pooled findings for several mental-health-related measurements and explored how different daily amounts and intervention lengths related to outcomes. The authors nevertheless emphasized heterogeneity and the need for high-quality trials before stronger clinical recommendations could be made. A newer review can add valuable information without resolving all earlier disagreements, especially when some included trials are small or use different preparations. See the 2022 review, 2024 review, and 2026 review.

How Much Did Stress Scores Improve?

The 2024 review's −4.72-point pooled difference is one of the clearest numerical findings, but its meaning depends on the scale being used. The Perceived Stress Scale measures how stressful people judge recent experiences to be. Its commonly used ten-item version ranges from 0 to 40, with higher scores generally indicating greater perceived stress. An average difference between groups is not the same as a guarantee that everyone will notice a particular amount of relief during a difficult week.

Other reviews use standardized mean differences, which express the result in units related to the variation of the scores rather than in questionnaire points. A standardized effect of −1.75 is not a 175% reduction in stress, and a lower cortisol value cannot be converted into a percentage improvement in emotional well-being. The practical question is whether the measured change was consistent across trials, meaningful to participants, and relevant to the people who might use that preparation. These details matter far more than an eye-catching number isolated from its research context.

Do Recent Meta-Analyses Agree?

Not entirely. The 2024 meta-analysis found significant pooled improvements in perceived stress and cortisol. In contrast, the 2025 meta-analysis found a significant reduction in cortisol but did not find a statistically significant improvement in perceived stress. The newer 2026 analysis again reported favorable overall findings, while continuing to flag uncertainty. This is a familiar pattern in developing scientific fields: evidence may point toward a possible benefit without settling every question about its size, consistency, or relevance.

Different conclusions do not necessarily mean that one research team made an error. Reviews may use different search dates, inclusion criteria, statistical methods, and definitions of suitable clinical outcomes. A few additional or excluded trials can affect a pooled estimate, especially when studies are relatively small. Rather than choosing whichever summary sounds most encouraging, readers should ask whether the same result appears repeatedly under comparable conditions. In ashwagandha research, the answer is stronger for some measured outcomes than for others.

Does Ashwagandha Reduce Stress and Cortisol?

Some clinical trials and pooled analyses have found lower cortisol levels and improved perceived-stress scores after supplementation with particular ashwagandha preparations. The outcomes do not always change together. Cortisol is a normal hormone involved in energy regulation and the stress response; perceived stress describes how people experience demands in daily life. A change in one measure does not prove a meaningful improvement in the other.

Cortisol is often presented as something everyone should try to lower, but that is not how normal physiology works. Levels naturally rise and fall across the day and can respond to sleep, exercise, illness, medications, and sampling conditions. A person who feels mentally overloaded does not automatically have an abnormal cortisol level, and one blood measurement does not describe the full daily pattern. The distinction matters because marketing phrases can make a complex hormone sound like a simple scorecard for wellness.

How Is Perceived Stress Measured?

Researchers commonly use the Perceived Stress Scale, or PSS, to ask how unpredictable, overwhelming, or controllable participants found their lives over a recent period. The widely used ten-question version produces scores from 0 to 40. Researchers compare scores at baseline and after the intervention, then examine whether the ashwagandha group changed more than a placebo group. This comparison helps account for improvements that might have happened anyway as jobs, schedules, or personal circumstances changed.

Questionnaires capture something laboratory measurements cannot: the participant's own experience. Yet responses can be influenced by expectations, memory, recent events, and differences in how people interpret questions. The PSS is not a diagnostic test for a psychiatric condition, and a change in score is not an automatic measure of improved work performance, relationships, or sleep. For the result to be persuasive, a study needs credible blinding, sensible comparison groups, and a clear explanation of how missing data were handled.

Does Lower Cortisol Mean Less Stress?

The 2025 review offers a particularly useful reality check. It reported a pooled cortisol difference of approximately −1.16 micrograms per deciliter compared with placebo, with a 95% confidence interval from −1.64 to −0.69. Its perceived-stress result was a standardized mean difference of −0.355, with a confidence interval from −1.188 to 0.47 and a p-value of 0.40. In other words, the cortisol finding met a conventional statistical threshold, but the perceived-stress finding did not.

That difference does not make the cortisol result meaningless. It shows that laboratory and lived-experience outcomes answer different questions. Cortisol values depend on collection time and measurement conditions, while stress questionnaires reflect people's interpretations of their daily circumstances. Neither should be treated as a universal substitute for the other. Consumers should be cautious when a product translates a study's hormone finding into a promise of feeling calm, sleeping better, or functioning differently without research that directly supports those outcomes. The 2025 review is especially instructive on this point.

2025 meta-analysis outcome	Reported estimate	Practical meaning
Cortisol	−1.16 µg/dL; 95% CI −1.64 to −0.69	Statistically significant pooled reduction
Perceived stress	SMD −0.355; 95% CI −1.188 to 0.47	No statistically significant pooled difference
Perceived-stress p-value	0.40	Does not meet the commonly used 0.05 threshold
Reported heterogeneity	I² = 50.9%	Moderate variation in the analyzed evidence

What Do Anxiety and Sleep Studies Show?

Several trials measured outcomes beyond stress, including anxiety-related questionnaires and sleep measures. The 2024 meta-analysis found a pooled difference of −2.19 on the Hamilton Anxiety Scale, with a 95% confidence interval from −3.83 to −0.55. That is a finding about an instrument used in specific research settings, not proof that a botanical supplement treats an anxiety disorder. Everyday stress, diagnosed anxiety conditions, and sleep disorders overlap in people's lives but are not interchangeable medical categories.

The National Institutes of Health summarizes small trials suggesting that some ashwagandha extracts may modestly improve sleep quality or duration. The NIH consumer fact sheet also stresses that preparations and doses varied, and the NCCIH guidance describes evidence for anxiety as unclear. Someone hoping to make evenings less hectic should not mistake these limited findings for a guaranteed sleep effect or a substitute for evaluation of persistent symptoms. It is reasonable to be interested in the research and equally reasonable to recognize its limits.

Are the Benefits Clinically Meaningful?

Statistical significance asks whether a result meets a statistical standard under the analysis used. Clinical importance asks whether the difference is large enough to matter in real life. A questionnaire can detect an average shift while leaving unanswered whether a participant felt better able to handle a long commute, a demanding deadline, or ordinary family responsibilities. Baseline stress levels, the scale used, and a person's circumstances can all influence what a particular numerical change means.

Most meta-analyses give group averages rather than individualized predictions. They cannot tell a person in advance whether a supplement will help, have little noticeable effect, or cause unwanted symptoms. A particularly useful study would report both validated measurements and outcomes that participants care about, such as everyday functioning and sustained well-being, while documenting adverse effects. Until those findings become more consistent, the sensible reading is that selected extracts have shown promising short-term signals, not that a particular person can expect a defined degree of improvement.

Which Ashwagandha Doses and Extracts Were Studied?

Ashwagandha studies have used different daily amounts, plant parts, and extract preparations, so no single research dose applies to every supplement. The 2024 review included approximately 125–600 mg daily over 30–90 days; other reviews assessed different regimens. A labeled milligram amount has limited meaning without knowing whether it refers to powder or extract, which plant part was used, and how the preparation was standardized.

The practical problem is easy to miss when comparing products online. Two bottles may each say 300 mg ashwagandha but contain distinctly different ingredients. A concentrated root extract is not automatically equivalent to whole-root powder, and an extract using both root and leaf material may differ from a root-only preparation. Research evaluates a particular preparation under defined conditions. The most informative comparison therefore starts with the actual ingredient specification, not whichever product carries the biggest front-label number.

What Daily Doses Did Trials Use?

The 2022 meta-analysis explored a dose-response pattern and reported favorable modeled findings for stress within a 300–600 mg/day range. In the 2024 review, included trials generally used 125–600 mg/day. The 2025 review required studies to use at least 250 mg/day, and the 2026 dose-response analysis reported more favorable findings in some subgroups using at most 500 mg/day. These are descriptions of the research that qualified for particular analyses; they are not instructions for choosing or changing a personal dose.

A dose-response analysis is also not proof that more is better. Different ingredient concentrations, study populations, and measurement methods can influence the apparent pattern. A milligram quantity on its own cannot show that two products are chemically or clinically comparable. Before treating a trial result as relevant to a retail supplement, it helps to know the botanical name, plant part, daily extract quantity, standardization, and whether the formula contains other active ingredients. Those details make a comparison possible, even though they still cannot guarantee the same outcome.

Research source	Studied amount or eligibility rule	Duration or interpretation
2022 review	Modeled favorable stress results around 300–600 mg/day	Low-certainty pooled evidence, not dosing advice
2024 review	125–600 mg/day	Approximately 30–90 days; mixed extract types
2025 review	Eligible trials used ≥250 mg/day	At least 2 weeks; cortisol and PSS outcomes differed
2026 review	Some analyses favored ≤500 mg/day	Some favorable patterns with interventions >8 weeks; subgroup findings are not prescriptions

How Long Did the Studies Last?

Many clinical trials lasted about six to eight weeks, while the 2024 review included interventions extending from roughly 30 to 90 days. The 2025 analysis also included trials lasting at least two weeks. Such periods tell us when researchers assessed outcomes, not precisely when a supplement begins working. If an eight-week study finds a group difference at its final visit, that does not show that everyone felt a benefit on the first day, or that the same difference would appear after a year.

The 2026 review noted more favorable results in some analyses involving interventions longer than eight weeks. That observation is interesting, but longer duration is not automatically safer or more effective for every individual. The NIH indicates that safety information is mostly limited to short-term use, commonly up to approximately three months, with insufficient data on long-term exposure. A useful distinction is between how long something was studied, when an outcome was measured, and how long someone can safely continue using it. Current evidence does not provide one universal answer to all three.

How Do Root and Root-Leaf Extracts Differ?

Ashwagandha products may use roots, combinations of root and leaf material, or powdered botanical material. The relative amounts of naturally occurring compounds can differ between plant parts, and extraction processes further influence the resulting ingredient. Withanolides are frequently used as standardization markers, but the percentage printed on a label does not by itself prove stronger effects. A standardized extract provides a more identifiable specification; it does not remove the need to examine evidence relevant to that specific preparation.

For example, a hypothetical 300 mg extract standardized to 5% withanolides would contain 15 mg of the specified standardized fraction by simple arithmetic. That calculation says nothing about whether the extract is equivalent to a preparation used in a different clinical trial. It also says nothing conclusive about safety or effectiveness. When reading research, consumers should look for the botanical name Withania somnifera, the plant part, extract amount, and any clearly documented standardization. These details prevent misleading milligram-for-milligram comparisons between products that may be quite different.

What Is Known About KSM-66 Ashwagandha?

KSM-66 is a branded, root-based ashwagandha extract that has been investigated in clinical studies. Identifying a specific extract is helpful because it narrows the ingredient being discussed and can make comparisons with research more meaningful. Still, the presence of a trademarked ingredient does not establish that every finished supplement containing it has been studied. Researchers evaluate defined amounts, study populations, intervention periods, and outcomes. A finished formula may differ in several important respects even when it includes the same named extract.

AirVigor's Night Calm Liquid Sticks – Blackberry are presented as a melatonin-free evening-wellness format with KSM-66 ashwagandha, L-theanine, magnesium glycinate, chamomile, and lemon balm. The convenience of 30 individually packaged ready-to-drink sticks is a product-format characteristic, not a proven clinical advantage. The supplied product records have not yet verified every exact ingredient quantity from a final Supplement Facts label, so results from isolated ashwagandha trials should not be attributed to this finished combination. The distinction protects consumers from assuming that an appealing ingredient story is the same as finished-product evidence.

How Reliable Is the Scientific Evidence?

The evidence is promising but not definitive. Randomized trials offer useful information, and pooled studies can reveal patterns, yet many ashwagandha investigations are small, relatively short, and different from one another. Reviews have identified substantial heterogeneity and, in some cases, low certainty of evidence. The most reliable interpretation considers study design, consistent results, meaningful outcomes, and the limits of extrapolating findings to commercial products.

A meta-analysis is a method, not a stamp of guaranteed truth. Its quality depends on the original experiments and the decisions researchers make when selecting and combining them. If studies use different formulations and stress scales, a single pooled number may tell us less about a particular consumer's experience than the headline suggests. That does not make meta-analysis unhelpful. It means careful readers need to look beyond whether the calculated result has a p-value below a familiar threshold.

How Strong Are the Clinical Trials?

A randomized controlled trial can reduce several important sources of bias, particularly when allocation is concealed, participants and assessors are blinded, and outcomes are specified in advance. These precautions matter when the main outcome is a questionnaire about feelings. If participants can guess which group they are in, expectations may influence their answers. Investigators also need to explain how many people completed the study, how missing data were handled, and whether negative results were reported alongside positive ones.

The 2022 review rated certainty as low despite favorable pooled stress and anxiety estimates. The 2025 review described generally moderate risk-of-bias concerns and noted weaknesses in allocation concealment in some studies. Those are not technical footnotes that consumers can safely ignore. They affect how confidently an average result can be attributed to the intervention. Better evidence would come from larger, independently conducted trials using clearly documented preparations, consistent measurements, and transparent reporting of benefits and adverse events.

What Explains Conflicting Research Results?

Conflicting findings can begin with very ordinary differences: one study recruits people with high baseline stress, another recruits healthier volunteers, and another measures cortisol at a different time of day. Extract composition, daily amount, intervention length, and questionnaires can also vary. When a review combines these studies, the statistical model may need to account for effects that are genuinely different rather than assuming every trial tested exactly the same intervention.

The disagreement between the 2024 and 2025 reviews is instructive rather than embarrassing. One analysis found significant pooled improvement in perceived stress, while the other did not, despite finding lower cortisol. Different eligibility rules and included trials can shift the estimate. Publication and selective-reporting biases are additional possibilities to evaluate, not conditions to assume without evidence. A credible summary keeps the disagreement visible and asks which outcomes are most directly supported. Choosing only the most positive review would make the science seem simpler than it is.

Do Study Size and Design Affect the Findings?

A small trial may detect a real signal, but it usually estimates the size of that signal less precisely than a larger, well-conducted trial. With limited participants, a few unusually strong or weak responses can influence the average. Combining many small experiments may improve statistical precision, yet it cannot undo shared weaknesses such as unreliable blinding or inconsistent ingredient characterization. The participants also have to resemble the population to which the conclusions are being applied.

Heterogeneity describes how much study results differ beyond ordinary sampling variation. In 2022, the review reported I² values of 83.1% for stress and 93.8% for anxiety, indicating substantial variation. The 2025 analysis reported I² of about 50.9% in its pooled evidence. These statistics do not, by themselves, prove that an effect is absent or present; they warn that one average may not represent all studies equally well. Readers should consider the size of each trial, follow-up length, measurement choices, and differences in preparation before treating a pooled estimate as a personal forecast.

What Are the Remaining Research Gaps?

Long-term information is a major gap. Many trials conclude after several weeks or a few months, so they cannot establish how benefits or adverse effects evolve with prolonged use. Larger studies with more diverse participants would also help researchers understand whether outcomes differ with age, baseline stress, medication use, or other health factors. More consistent reporting of the plant part and standardized extract would make it easier to compare apparently similar investigations.

Future research would be more useful if it measured outcomes that matter in ordinary life as well as laboratory markers: the ability to manage daily responsibilities, sleep-related functioning, and sustained well-being, using validated methods. Independent replication and thorough adverse-event reporting are equally important. The 2026 review increased the number of eligible trials but still called for better-quality research. For now, the fair conclusion is that certain preparations show potential in short-term studies while key questions about consistent effects, ideal trial conditions, and long-term safety remain unresolved.

How Should Consumers Interpret These Findings?

Consumers should use ashwagandha research to understand what was tested, not as proof that every product will deliver the same result. A useful label identifies the ingredient form, serving quantity, other ingredients, and warnings. Individual medical circumstances matter, especially during pregnancy, with thyroid or autoimmune conditions, or when taking medications. Convenience can help a routine fit real life, but it does not replace safety or product-specific evidence.

Choosing a supplement is ultimately a comparison between the evidence and the exact product in front of you. A trial involving a root extract at a defined amount does not automatically support claims about an unrelated powder, gummy, or multi-ingredient liquid. Product information should help a person understand what is present and what remains unknown. That clarity is more valuable than broad promises about eliminating stress, balancing hormones, or producing a predictable result within a fixed number of minutes.

Who Should Avoid Ashwagandha or Seek Medical Advice?

The NCCIH advises avoiding ashwagandha during pregnancy and not using it while breastfeeding. It is also not recommended for people preparing for surgery or those with autoimmune or thyroid disorders. Possible interactions include medications for diabetes or high blood pressure, thyroid hormones, sedatives, anticonvulsants, and immunosuppressants. Individuals with hormone-sensitive prostate cancer should avoid it. These cautions matter even when a product is sold without a prescription.

Ashwagandha can cause drowsiness, stomach upset, diarrhea, or vomiting, and rare cases of liver injury have been linked to products containing it. Someone who develops signs such as jaundice, dark urine, or persistent unusual symptoms after taking a supplement should stop using it and seek medical evaluation. Persistent stress, significant sleep disruption, or symptoms affecting daily functioning also deserve professional attention. Short-term tolerability reported in trials is not a guarantee of safety for everyone, particularly where other conditions or medicines are involved.

What Should You Check on a Supplement Label?

Start with the botanical name, plant part, and preparation type. A label that identifies a standardized root extract tells you more than one that lists only a generic herb name. Then read the serving size and actual amount per serving, distinguishing individual ingredient quantities from a combined blend total. Review other active ingredients, warnings, and directions. If two products both feature ashwagandha, there may still be meaningful differences in formulation and exposure.

Quality descriptions are most useful when they can be checked, rather than when they rely on attractive words such as premium or pure. A manufacturer should not be assumed to hold specific certifications or conduct particular tests without evidence. Consumers using multiple supplements should also look for overlapping ingredients, especially minerals and botanicals that may appear in more than one formula. Transparent labeling does not prove a clinical benefit, but it provides the information needed to compare products responsibly and discuss them with a healthcare professional when appropriate.

Can Clinical Findings Apply to Combination Supplements?

Not automatically. The result of a trial using one standardized extract belongs to that tested intervention, including its dose, duration, and study population. A commercial combination may include other botanicals, amino acids, or minerals, and the finished product might contain a different ashwagandha quantity. Even if each ingredient has a separate research history, that does not demonstrate the combined effects of a particular formulation or show that the effects can be added together.

This distinction is relevant to evening-wellness blends containing ashwagandha alongside ingredients such as L-theanine, magnesium, or chamomile. The right questions are what each ingredient contributes to the formula, how much is actually present, and whether there are relevant interactions or duplicate exposures across a person's existing routine. Ingredient-level research is useful context, but finished-product claims require evidence appropriate to the finished formulation. A careful brand makes that boundary clear instead of borrowing outcomes from studies on different products.

How Does Ashwagandha Fit Into Everyday Wellness?

Stress is influenced by more than one ingredient. Workloads, sleep opportunities, nutrition, physical activity, relationships, and underlying health can all shape how someone feels. For many people, building a manageable evening routine, protecting time for sleep, eating regularly, and finding realistic opportunities for movement are worthwhile starting points. A supplement may be considered when appropriate, but it cannot remove stressful circumstances or substitute for needed medical care.

Convenience can still make an appropriate routine easier to follow. Someone who travels may prefer individual liquid sticks, while another person may find a straightforward capsule simpler. AirVigor's emphasis on clear formulas and practical formats fits this real-life consideration, provided convenience is not confused with proof of clinical effectiveness. The strongest purchasing decision is neither blind enthusiasm nor automatic rejection. It is an informed comparison of the studies, the actual Supplement Facts panel, personal safety factors, and the kind of routine someone can realistically maintain.

The overall picture is encouraging but qualified. Reviews of randomized trials report favorable stress-related findings for some ashwagandha extracts, including changes in perceived-stress scores and cortisol, yet not all analyses agree. Differences in extracts, follow-up, and study quality make universal promises inappropriate. For a consumer, the useful next step is not to chase the highest dose or the boldest claim, but to understand the preparation, check its safety information, and decide whether it fits their circumstances and expectations.

Frequently Asked Questions

1. Does a meta-analysis prove that ashwagandha reduces stress?

No single meta-analysis proves a guaranteed effect for everyone. Reviews published in 2022, 2024, and 2026 reported favorable pooled findings, but they also identified differences between trials and limitations in evidence certainty. A 2025 review did not find a statistically significant effect on perceived stress even though cortisol was lower. The fairest conclusion is that selected preparations may offer potential benefits under the studied conditions, while the size and consistency of effects are still being investigated.

2. How long did ashwagandha take to show results in clinical trials?

Many trials assessed outcomes after approximately six to eight weeks, and the 2024 review included interventions lasting about 30 to 90 days. These study durations are not promises of when an individual will feel a change. Researchers measure outcomes at scheduled visits, which may not reveal exactly when changes began. The evidence also does not establish that increasing the duration indefinitely will provide greater benefit or remain safe, because long-term information is limited.

3. Does ashwagandha lower cortisol even when stress scores do not change?

That pattern appeared in the 2025 meta-analysis. Its pooled cortisol difference was about −1.16 µg/dL, while the perceived-stress result did not meet a conventional statistical significance threshold. Cortisol is a normal hormone that varies by time of day and health circumstances, so a laboratory change does not automatically mean someone feels calmer. The finding highlights the importance of interpreting hormone measurements alongside validated questionnaires and everyday functioning rather than treating one as proof of the other.

4. What ashwagandha dosage was used in stress research?

The 2024 review included studies using approximately 125 to 600 mg per day, and the 2022 review identified favorable modeled stress-related findings around 300 to 600 mg daily. Those figures are descriptions of trial protocols, not a universal recommended dose. Preparations differ in plant part, extraction method, and standardization, which means equal milligram amounts may not represent equivalent ingredients. The current product label and individual health circumstances matter more than copying a number from a study.

5. Is KSM-66 the same as every other ashwagandha extract?

No. KSM-66 is an identifiable branded root extract, while other ashwagandha products may use different plant parts, extraction processes, or concentrations. Research involving one specified preparation does not automatically establish outcomes for a different one. Even a finished supplement containing KSM-66 may include additional ingredients or different serving amounts from those investigated in a clinical trial. Consumers can make better comparisons by checking the complete ingredient identity and Supplement Facts rather than relying on the botanical name alone.

6. Is ashwagandha safe to take every day for months?

Many short-term studies found ashwagandha reasonably well tolerated for up to about three months, but longer-term safety has not been established. It may cause digestive discomfort or drowsiness, and rare liver-injury reports have been associated with ashwagandha-containing products. It should be avoided during pregnancy and breastfeeding, with additional cautions for thyroid or autoimmune conditions and certain medications. Anyone considering ongoing use, especially with health conditions or prescriptions, should consult an appropriate healthcare professional rather than assuming that natural means risk-free.